Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthias Eiber

Showing results (301-310 of 377) with videos related to

Pageof 38
Sort By:
European Urology|April 8, 2018
<sup>99m</sup>Technetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate CancerTobias Maurer, Stephanie Robu, Margret Schottelius, et al.
The Journal of Experimental Medicine|November 17, 2017
Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptorsCharalambos Kaittanis, Chrysafis Andreou, Haley Hieronymus, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 13, 2021
The added value of PSMA PET/MR radiomics for prostate cancer stagingEsteban Lucas Solari, Andrei Gafita, Sylvia Schachoff, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 19, 2021
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PETFrancesco Ceci, Daniela E Oprea-Lager, Louise Emmett, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 19, 2023
Long-Term Nephrotoxicity of <sup>177</sup>Lu-PSMA Radioligand TherapyLisa Steinhelfer, Lukas Lunger, Lisena Cala, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 30, 2023
PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [<sup>177</sup>Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective StudyMasatoshi Hotta, Andrei Gafita, Vishnu Murthy, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 15, 2018
Potential Impact of <sup>68</sup>Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate CancerJeremie Calais, Amar U Kishan, Minsong Cao, et al.
Cancers|November 26, 2022
PSMA PET for the Evaluation of Liver Metastases in Castration-Resistant Prostate Cancer Patients: A Multicenter Retrospective StudySusanna Mattoni, Andrea Farolfi, Fabio Formaggio, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 15, 2022
Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter StudyAndrei Gafita, Isabel Rauscher, Manuel Weber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 24, 2016
Radiation Dosimetry for <sup>177</sup>Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor LesionsShozo Okamoto, Anne Thieme, Jakob Allmann, et al.
Pageof 38

Showing results (301-310 of 377) with videos related to

Sort By:
Pageof 38
European Urology|April 8, 2018
<sup>99m</sup>Technetium-based Prostate-specific Membrane Antigen-radioguided Surgery in Recurrent Prostate CancerTobias Maurer, Stephanie Robu, Margret Schottelius, et al.
The Journal of Experimental Medicine|November 17, 2017
Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptorsCharalambos Kaittanis, Chrysafis Andreou, Haley Hieronymus, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 13, 2021
The added value of PSMA PET/MR radiomics for prostate cancer stagingEsteban Lucas Solari, Andrei Gafita, Sylvia Schachoff, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 19, 2021
E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PETFrancesco Ceci, Daniela E Oprea-Lager, Louise Emmett, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 19, 2023
Long-Term Nephrotoxicity of <sup>177</sup>Lu-PSMA Radioligand TherapyLisa Steinhelfer, Lukas Lunger, Lisena Cala, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 30, 2023
PSMA PET Tumor-to-Salivary Gland Ratio to Predict Response to [<sup>177</sup>Lu]PSMA Radioligand Therapy: An International Multicenter Retrospective StudyMasatoshi Hotta, Andrei Gafita, Vishnu Murthy, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 15, 2018
Potential Impact of <sup>68</sup>Ga-PSMA-11 PET/CT on the Planning of Definitive Radiation Therapy for Prostate CancerJeremie Calais, Amar U Kishan, Minsong Cao, et al.
Cancers|November 26, 2022
PSMA PET for the Evaluation of Liver Metastases in Castration-Resistant Prostate Cancer Patients: A Multicenter Retrospective StudySusanna Mattoni, Andrea Farolfi, Fabio Formaggio, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 15, 2022
Novel Framework for Treatment Response Evaluation Using PSMA PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer (RECIP 1.0): An International Multicenter StudyAndrei Gafita, Isabel Rauscher, Manuel Weber, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|September 24, 2016
Radiation Dosimetry for <sup>177</sup>Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: Absorbed Dose in Normal Organs and Tumor LesionsShozo Okamoto, Anne Thieme, Jakob Allmann, et al.
Pageof 38